Pacira BioSciences · ISIN: US6951271005

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

NEW ORLEANS, Jan. 31, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX),...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 01.02.2025 | 04:50
01 February 2025 04:50AM
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
NEW ORLEANS, Jan. 31, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX),...
© PR Newswire
31 January 2025 11:41PM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline....
© PR Newswire
31 January 2025 11:45AM
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t...
© PR Newswire
31 January 2025 12:18AM
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
© PR Newswire
29 January 2025 04:00AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
© PR Newswire
28 January 2025 11:45AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t...
© PR Newswire
27 January 2025 10:16PM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, y...
© PR Newswire
27 January 2025 11:45AM
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encoura...
© PR Newswire
26 January 2025 10:00PM
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alle...
© BusinessWire
25 January 2025 04:50AM
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
NEW ORLEANS, Jan. 24, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX), if they purchased the Company's securities between August...
© PR Newswire
24 January 2025 10:00PM
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ: PCRX) and certain of its officers....
© PR Newswire
24 January 2025 11:45AM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t...
© PR Newswire
23 January 2025 09:20PM
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
© PR Newswire
23 January 2025 11:45AM
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
NEW YORK, Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encoura...
© PR Newswire
21 January 2025 11:55PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
© PR Newswire
21 January 2025 11:45AM
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t...
© PR Newswire
20 January 2025 05:15PM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
NEW YORK, Jan. 20, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, y...
© PR Newswire
20 January 2025 11:45AM
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PCRX
NEW YORK, Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encoura...
© PR Newswire
18 January 2025 04:50AM
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
NEW ORLEANS, Jan. 17, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX),...
© PR Newswire
17 January 2025 10:00PM
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alle...
© BusinessWire
17 January 2025 11:45AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t...
© PR Newswire
17 January 2025 09:27AM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ: PCRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
© PR Newswire
16 January 2025 10:00PM
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ: PCRX) and certain of its officers....
© PR Newswire
16 January 2025 11:45AM
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encoura...
© PR Newswire
15 January 2025 05:44PM
PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities b...
© BusinessWire
15 January 2025 05:22PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi &...
© PR Newswire
15 January 2025 07:46AM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, y...
© PR Newswire
15 January 2025 02:03AM
Stockholder Notice: Robbins LLP Informs Stockholders of the Pacira BioSciences, Inc. Class Action Lawsuit
SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and provi...
© PR Newswire
14 January 2025 07:14PM
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
© BusinessWire
14 January 2025 03:19AM
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). Pacira is a pharmaceutical company. For more information, subm...
© BusinessWire
06 December 2024 01:00PM
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to...
© Globe Newswire
14 November 2024 03:05PM
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- -- Poster to be presented at ACR Convergence annual meeting --...
© Globe Newswire
30 October 2024 12:00PM
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET....
© Globe Newswire
21 October 2024 12:00PM
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience...
© Globe Newswire
03 October 2024 12:00PM
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medica...
© Globe Newswire
26 September 2024 12:00PM
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201 (enekinragene...
© Globe Newswire
25 September 2024 02:15PM
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Direct...
© PR Newswire
09 August 2024 07:21PM
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not...
© Globe Newswire
10 July 2024 08:19PM
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment –...
© Globe Newswire
30 May 2024 12:00PM
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company...
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.